Switzerland· 69531002
Nintedanib Spirig HC 150 mg, Weichkapsel
A nintedanib product containing nintedanibum, registered in Switzerland by Spirig HealthCare AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Nintedanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Nintedanib · ATC L01EX09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of nintedanib costs, country by country.
Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.
- Switzerland: $34.12 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Nintedanib · price per daily dose (0.38 g)
USD · FX 28 Sept 2026
- US United States$51.13 (acquisition cost)
- CH Switzerland$34.12
The record
At a glance
Swissmedic (Switzerland)- Active substance
- nintedanibum
- Manufacturer
- Spirig HealthCare AG
- Country
- Switzerland (CH)
- ATC code
- L01EX09
- ATC class
- Nintedanib
- Defined daily dose
- 0.38 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680695310023Blist 60 StkCHF 665.4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
160 interactions on record for nintedanib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nintedanib · interactions on record
160 records
- 21 severe
- 139 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- DexamethasoneH02AB02severe
- RifampicinJ04AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nintedanib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandAgarfNorameda UAB
- SpainNINTEDANIB ACCORD 150 MG CAPSULAS BLANDAS EFGAccord Healthcare S.L.U.
- SwedenNintedanib Accord 150 mg Kapsel, mjukAccord Healthcare S.L.U.
- PolandNintedanib AccordAccord Healthcare S.L.U.
- FranceNINTEDANIB ACCORD 150 mg, capsule molleACCORD HEALTHCARE (ESPAGNE)
- IrelandOfev 150 mg Soft capsuleBoehringer Ingelheim International GmbH
- NorwayNintedanib AccordAccord Healthcare S.L.
- NetherlandsGevesla 100 mg, zachte capsulesSandoz B.V.
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Nintedanib Cipla, Nintedanib Ratiopharm
- Belgium · Nintedanib Accordpharma, Nintedanib Eg
- Cyprus · Nintedanib Teva
- Czechia · Nintedanib Glenmark, Nintedanib Sandoz
- Germany · Nintedanib, Nintedanib 1 A Pharma
- Denmark · Nintedanib "sandoz", Nintedanib Glenmark
- Estonia · Agarf, Nintedanib Sandoz
- Spain · Nintedanib, Nintedanib Accordpharma
- Finland · Nintedanib Glenmark, Nintedanib Ratiopharm
- France · Nintedanib Arrow, Nintedanib Biogaran
- United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Accord Healthcare
- Greece · Nifib, Nindraf
- Croatia · Gevesla, Nintedanib Accordpharma
- Hungary · Nintedanib Accordpharma, Nintedanib Onkogen
- Ireland · Nintedanib Accordpharma, Nintedanib Clonmel
- Iceland · Agarf, Nintedanib Accord
- Italy · Nintedanib Accordpharma, Nintedanib Aurobindo
- Liechtenstein · Nintedanib Accord, Nintedanib Viatris
- Lithuania · Agarf, Nintedanib Sandoz
- Luxembourg · Nintedanib Eg, Nintedanib Eurogenerics
- Latvia · Agarf, Nintedanib Sandoz
- Malta · Nifiden Adalvo, Nintedanib Adalvo
- Netherlands · Gevesla, Nintedanair
- Norway · Nintedanib Accord, Nintedanib Devatis
- Poland · Nintedanib, Nintedanib Accordpharma
- Portugal · Nintedanib Accordpharma, Nintedanib Eugia
- Romania · Gevesla, Nintedanib Dr. Reddy’s
- Sweden · Nintedanib Devatis, Nintedanib Glenmark
- Slovenia · Nintedanib Accordpharma, Nintedanib Stada
- Slovakia · Nintedanib Stada, Nintedanib Teva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d957ae11-adaf-4c66-a7a2-4bfaad3801f5 GET /v1/drugs/d957ae11-adaf-4c66-a7a2-4bfaad3801f5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "nintedanibum 150 mg",
"valid_from": "2026-01-01",
"limitations": "[{\"description\":\"<p>Für alle vergütungspflichtigen Indikationen gilt:<br>Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes im Rahmen der erstmaligen Indikationsstellung. Für die Behandlung mit NINTEDANIB SPIRIG HC ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Originalpräparat oder ein anderes Generikum besteht.</p>\",\"costApproval\":null,\"indication\":\"22044.XX\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>IPF</strong><br>Diagnosestellung der idiopathischen Lungenfibrose (IPF) gemäss internationalen Empfehlungen (ATS/ERS) durch spezialisierte Zentren für IPF bzw. durch entsprechend qualifizierte Fachärzte für Pneumologie.</p>\\n<p>Folgender Indikationscode ist zu übermitteln: 22044.01</p>\",\"costApproval\":null,\"indication\":\"22044.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>PF-ILD</strong><br>Diagnosestellung von chronischen fibrosierenden interstitiellen Lungenerkrankungen (ILDs) mit einem progressiven Phänotyp gemäss internationalen Empfehlungen (ATS/ERS) durch spezialisierte Zentren für Pneumologie bzw. durch entsprechend qualifizierte Fachärzte für Pneumologie.</p>\\n<p>Eine Therapieweiterführung kann durch spezialisierte Zentren für Pneumologie oder Rheumatologie bzw. durch entsprechend qualifizierte Fachärzte für Pneumologie oder Rheumatologie erfolgen.</p>\\n<p>Folgender Indikationscode ist zu übermitteln: 22044.02</p>\",\"costApproval\":null,\"indication\":\"22044.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"},{\"description\":\"<p><strong>SSc-ILD</strong><br>Diagnosestellung der mit systemischer Sklerose assoziierten interstitiellen Lungenerkrankung (SSc-ILD) gemäss internationalen Empfehlungen (ATS/ERS/EULAR) durch spezialisierte Zentren für Pneumologie bzw. durch entsprechend qualifizierte Fachärzte für Pneumologie.</p>\\n<p>Eine Therapieweiterführung kann durch spezialisierte Zentren für Pneumologie oder Rheumatologie bzw. durch entsprechend qualifizierte Fachärzte für Pneumologie oder Rheumatologie erfolgen.</p>\\n<p>Folgender Indikationscode ist zu übermitteln: 22044.03</p>\",\"costApproval\":null,\"indication\":\"22044.03\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"}]",
"galenic_form": "Weichkaps 150 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2026-01-01",
"self_retention_pct": 10
}See everything about nintedanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.